Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Treatment with pioglitazone induced significant, reversible mitral regurgitation

In English

Författare

Summary, in English

There has in recent years been great concern about possible cardiac side effects of thiazolidinediones ( TZDs). We present a case-report of a 60 year-old male who developed significant mitral regurgitation during six months treatment with pioglitazone in parallel with laboratory indications of fluid retention. Echocardiography six months after discontinuation of medication showed regression of mitral regurgitation and the laboratory parameters were also normalized. It is noteworthy that six months treatment with pioglitazone could induce significant valve dysfunction, which was reversible, and this underlines the importance of carefully monitoring patients when placing them on treatment with TZDs.

Publiceringsår

2008

Språk

Engelska

Publikation/Tidskrift/Serie

Cardiovascular Diabetology

Volym

7

Issue

12

Dokumenttyp

Artikel i tidskrift

Förlag

BioMed Central (BMC)

Ämne

  • Endocrinology and Diabetes
  • Radiology, Nuclear Medicine and Medical Imaging

Status

Published

Forskningsgrupp

  • Genomics, Diabetes and Endocrinology
  • Clinical Physiology, Malmö

ISBN/ISSN/Övrigt

  • ISSN: 1475-2840